Françoise de Craecker
Director/Miembro de la Junta en X4 PHARMACEUTICALS, INC. .
Fortuna: 58 384 $ al 30/04/2024
Cargos activos de Françoise de Craecker
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Corporate Officer/Principal | 01/01/2014 | - |
| GENSIGHT BIOLOGICS S.A. | Director/Miembro de la Junta | 16/05/2021 | - |
| Independent Dir/Board Member | 16/05/2021 | - | |
| X4 PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 14/10/2021 | - |
| Independent Dir/Board Member | 14/10/2021 | - |
Historial de carrera de Françoise de Craecker
Antiguos cargos conocidos de Françoise de Craecker.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01/01/2018 | 01/09/2019 |
Raptor Pharmaceuticals Europe BV
 Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The company is based in Louveciennes, the Netherlands. | Corporate Officer/Principal | 01/07/2017 | 01/12/2017 |
Formación de Françoise de Craecker.
| Katholieke Universiteit Leuven | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Bélgica | 2 |
| Francia | 2 |
Operativa
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Europe BV
Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The company is based in Louveciennes, the Netherlands. | Commercial Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
